このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

固形腫瘍悪性腫瘍患者の PET スキャンに使用した場合の GEH200520/GEH200521 (18F) の安全性と忍容性を評価する研究

2026年9月22日 更新者:GE Healthcare

GEH200520 注射/GEH200521 (18F) 注射の安全性と忍容性、PET 画像、薬物動態、および治療後の画像

Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.

Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.

Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit. Two late imaging transfer expected post follow up visit. The estimated duration for subject participation in Part B is approximately 64 days.

調査の概要

研究の種類

介入

入学 (実際)

19

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Amsterdam、オランダ
        • Amsterdam UMC
      • Groningen、オランダ
        • UMC Groningen

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
  • The subject is male or female, ≥18 years of age.
  • Subject has a life expectancy ≥12 weeks.
  • Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Subject has an unresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma, or an unresectable stage III-IV melanoma.
  • Subject is eligible for ICI treatment per Investigator judgement.
  • Subject has at least 1 measurable tumour lesion documented on CT/magnetic resonance imaging (MRI) RECIST v1.1 during the last 12 months.
  • Subject has a tumour lesion(s) of which a biopsy can safely be obtained according to standard clinical care procedures.
  • Subject is male or female that agrees to adhere to the protocol contraception methods.

Exclusion Criteria:

  • Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
  • Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
  • Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
  • Subject has serious non-malignant disease or conditions that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has B or T cell lymphoma.
  • Subject has brain or bone-marrow metastasis that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has signs or symptoms of systemic infection within 2 weeks prior to imaging day.
  • Subject has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins or known allergy to the study IMP ingredients and/or the proposed ICI therapy.
  • Subject has any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the ICI treatment, or that may affect the interpretation of the results or render the subject at high risk from complications.
  • Subject has laboratory values out of range per protocol.
  • Subject has any safety laboratory test results (blood chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
  • Subject has had any major surgery within 4 weeks prior to enrollment.
  • Subject has been enrolled in another interventional clinical study within the 30 days before screening for this study, except for the study site IIS.
  • Subject is pregnant or planning to become pregnant or is breastfeeding.
  • Subject has a history of alcohol or drug abuse within the last year.
  • Subject has had treatment with systemic immunostimulatory agents within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to dosing with the IMP.
  • Subject has had treatment with systemic immunosuppressive medications within 2 weeks prior to dosing with the IMP.
  • Subject has received acute, low-dose, systemic immunosuppressant medications that, in the opinion of the Investigator, could compromise protocol objectives.
  • Subject has used systemic corticosteroids to treat inflammatory or autoimmune symptoms.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part A Cohort 1 - 1 mg dose

1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part A Cohort 2 - 2 mg dose

2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part A Cohort 3 - 4 mg dose

4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part A Cohort 4 - 8 mg dose

8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part A Cohort 5 (optional) - 12 or 15 mg dose

12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part A Cohort 6 - Optimal dose

Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

実験的:Part B

Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits

Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
パート A: IMP との因果関係による AE の発生率。
時間枠:パート A: 7 日
パート A: 7 日
パート A: IMP との因果関係に関する、国立がん研究所の有害事象に関する共通用語基準 (NCI CTCAE バージョン 5.0) による AE の重症度。
時間枠:パート A: 7 日
パート A: 7 日
ベースラインと比較した免疫チェックポイント阻害剤(ICI)治療サイクル後のGEH200521(18F)注射取り込みの経時変化を評価する。
時間枠:パート B: 50 日
パート B: 50 日

二次結果の測定

結果測定
メジャーの説明
時間枠
異なる GEH200520 注射質量線量で投与された場合の GEH200521 (18F) 注射の固定線量の放射線線量測定を、線源領域および全身の累積活動によって評価すること。
時間枠:7日
7日
パートAの被験者に異なるGEH200520注射質量用量を投与した場合のGEH200521(18F)注射陽電子放出断層撮影(PET)イメージングの最適なイメージング時間枠を評価する。
時間枠:7日
7日
GEH200521(18F)注射剤と一緒に投与してパートAの被検者に許容可能なPET画像品質を達成するためのGEH200520注射剤の適切な大量投与量を決定すること。
時間枠:7日
7日
免疫原性を評価するために、治療誘発性の抗薬物抗体応答の発生率を介して、パートAの被験者に固定用量のGEH200521(18F)注射剤とともに投与されたさまざまなGEH200520注射剤の大量用量の単回注射後。
時間枠:7日
7日
AE/SAE/AESI の発生率、重症度、訪問間の変化の収集
時間枠:50日
50日
GEH200521 (18F) 注射の体内分布と腫瘍への取り込みを評価すること。
時間枠:50日
50日
腫瘍 GEH200521 (18F) 注射による取り込み (SUV 値) と生検サンプル/切除病変からの免疫細胞 CD8+ 発現スコア (利用可能な場合) との関係を、パート B 被験者の IHC 結果に基づいて評価する。
時間枠:50日
50日
可能な場合、パート B 被験者の固形腫瘍における応答評価基準 (RECIST) v1.1 に従って、腫瘍 GEH200521 (18F) 注射取り込みの変化をコンピューター断層撮影 (CT) 画像評価の変化と比較する。
時間枠:50日
50日
[18F]-フルオロデオキシグルコース (FDG) スキャンに従って、腫瘍 GEH200521 (18F) 注射摂取量の変化とコンピューター断層撮影 (CT) 画像評価の変化を比較する (パート B の被験者が利用可能な場合)。
時間枠:50日
50日
パートBの被験者にGEH200521(18F)注射液とGEH200520注射液を複数回投与した後の、治療誘発性の抗薬物抗体応答の発生率による免疫原性を比較する。
時間枠:50日
50日
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
時間枠:7 days

The PK parameter to be assessed: AUC

7 days
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
時間枠:7 days

The PK parameter to be assessed: Cmax

7 days
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
時間枠:7 days

The PK parameter to be assessed: CL

7 days
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
時間枠:7 days

The PK parameter to be assessed: V

7 days
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
時間枠:7 days

The PK parameter to be assessed: t1/2

7 days
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
時間枠:7 days

Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term

7 days
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
時間枠:Baseline, 24 hours, 7 days post IMP administration

The findings in the physical exam pre and post-administration will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
時間枠:Baseline, 24 hours, 7 days post IMP administration

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, 24 hours, 7 days post IMP administration
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
時間枠:Baseline, 24 hours, 7 days post IMP administration

Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.

Baseline, 24 hours, 7 days post IMP administration
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
時間枠:Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
時間枠:Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
時間枠:Baseline, 2 hours, 24 hours, 7 days post IMP administration

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
時間枠:Baseline, 2 hours, 24 hours, 7 days post IMP administration

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, 2 hours, 24 hours, 7 days post IMP administration
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
時間枠:Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration physical exam status values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
時間枠:Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
時間枠:Baseline, Day 15, Day 36, Day 50

In this context, baseline is defined as the pre-treatment assessment at the screening visit. The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
時間枠:Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration heart rate values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
時間枠:Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration blood pressure values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
時間枠:Baseline, Day 15, Day 36, Day 50

The occurrence of post-administration body temperature values outside the normal limits will be summarized.

Baseline, Day 15, Day 36, Day 50
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
時間枠:Baseline, Day 15, Day 36, Day 50

Descriptive statistics will be used to describe the observed values and change from baseline.

Baseline, Day 15, Day 36, Day 50
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
時間枠:50 days

The PK parameter to be assessed: AUC

50 days
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
時間枠:50 days

The PK parameter to be assessed: Cmax

50 days
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
時間枠:50 days

The PK parameter to be assessed: CL

50 days
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
時間枠:50 days

The PK parameter to be assessed: V

50 days
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
時間枠:50 days

The PK parameter to be assessed: t1/2

50 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Ravi Karra, MD、GE Healthcare

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月27日

一次修了 (実際)

2026年8月4日

研究の完了 (実際)

2026年8月4日

試験登録日

最初に提出

2022年10月11日

QC基準を満たした最初の提出物

2022年11月17日

最初の投稿 (実際)

2022年11月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • GE-269-001
  • 2024-515218-42-00 (Ctis)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する